Literature DB >> 6638932

Acquired coagulopathy owing to parenteral cefamandole: renal failure as a predisposing factor.

J C Chang.   

Abstract

Within a span of four months at a 550 bed community hospital, four elderly patients who had been taking cefamandole for various infections developed a severe coagulopathy within 10 days after initiation of cefamandole. All patients had a prolonged prothrombin time and activated partial thromboplastin time with a marked decrease of the vitamin K dependent clotting factors II, VII, IX, X, and also were found to have mild to moderate renal function impairment. The coagulopathy was promptly corrected to normal with or without treatment of vitamin K and/or fresh frozen plasma when the drug was discontinued. Treatment with vitamin K while on cefamandole also corrected the coagulation abnormalities and in vitro cefamandole had no direct effect on prothrombin time and activated partial thromboplastin time in therapeutic concentrations. These clinical and laboratory observations and the nature of high excretion rate of cefamandole in bile suggest cefamandole induced coagulopathy is caused by decreased vitamin K synthesis, probably secondary to rapid depletion of vitamin K producing intestinal organisms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6638932

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  3 in total

Review 1.  Adverse reactions and interactions with newer cephalosporin and cephamycin antibiotics.

Authors:  S R Norrby
Journal:  Med Toxicol       Date:  1986 Jan-Feb

2.  Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit?

Authors:  G Agnelli; A Del Favero; P Parise; R Guerciolini; B Pasticci; G G Nenci; F Ofosu
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

3.  Signal Detection of Pediatric Drug-Induced Coagulopathy Using Routine Electronic Health Records.

Authors:  Xiaolu Nie; Yuncui Yu; Lulu Jia; Houyu Zhao; Zhenping Chen; Liqiang Zhang; Xiaoling Cheng; Yaqi Lyu; Wang Cao; Xiaoling Wang; Xiaoxia Peng
Journal:  Front Pharmacol       Date:  2022-07-20       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.